As the US Supreme Court mulls the so-called pay-for-delay schemes of the pharmaceutical industry, major drugstore retail chain Walgreen Co. has reportedly acquired a majority ownership stake of a pharmaceutical wholesaler, giving Walgreens a major upper-hand when negotiating drug prices. Walgreens currently has a supply agreement with AmerisourceBergen Corp. in a 10-year deal. Now, Walgreens will hold a majority stake in the company, while European retailer Alliance Boots will hold a minority stake. The contract allows Walgreens and Boots to buy up to 7 percent of AmerisouceBergen’s shares as well as warrants to pursue another 16 percent. The deal is just a further expansion of Walgreen’s $7 billion investment in global expansion; if Walgreens pursues its ability to purchase another 16 percent in 2015, the chain will have fully acquired AmerisourceBergen. The pharmaceutical wholesaler supplies brand name and generic drugs to Walgreens.
Featured News
Judge Orders Pause on Nexstar-Tegna Integration Amid Antitrust Challenge
Mar 29, 2026 by
CPI
Apple Hires Former Google Executive to Lead AI Product Marketing Push
Mar 29, 2026 by
CPI
FCC Warns NFL Risks Antitrust Trouble as More Games Move to Streaming
Mar 29, 2026 by
CPI
DOJ Issues Subpoenas in Paramount–Warner Bros. Discovery Merger Probe
Mar 29, 2026 by
CPI
Fannie Mae to Accept Crypto-backed Mortgages for the First Time
Mar 29, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Competitor Collaborations
Mar 26, 2026 by
CPI
Between Scylla and Charybdis – Navigating Transatlantic Antitrust Currents
Mar 26, 2026 by
Tilman Kuhn & Niklas Brüggemann
Cartel Enforcement Moves Into the Labor Market: Trends and Implications
Mar 26, 2026 by
Andreas Kafetzopoulos & Caroline Janssens
Rethinking Buy-Side Antitrust “Group Boycotts”
Mar 26, 2026 by
Craig Falls & Brendan McGuire
Positive Collaborations: The Tools Available to Competition Authorities to Encourage Beneficial Interactions Between Competitors
Mar 26, 2026 by
Rona Bar-Isaac & Thomas Withers